SeaStar Medical Holding Corp (ICUCW) stock
Close on Oct 30, 2026Market cap $9.87MP/E –Yield –
SeaStar Medical Holding Corp grew revenue 123.6% to $1.71M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $9.87M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.87M
- P/E ratio
- –
- Price to sales
- 5.76
- Price to book
- 2.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.71M
- Net income
- -$13.63M
- EPS, diluted
- -$3.93
- Book value per share
- $1.05
- Diluted shares
- 4M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $0.02
- Open
- $0.01
- Day's range
- $0.01 – $0.01
- Volume
- 140,859
- Average volume (20 days)
- 28,900
- Beta (5 years)
- 0.86
- 52-week range
- $2.07 – $6.00
- RSI (14 days)
- 35.4
- Volatility (1 year)
- 111.9%
- Relative volume
- 0.70×
- WACC
- 9.3%
Market cap history
Month-end market cap since 2023, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 30, 2026. The S&P 500 is measured by the SPY fund.
| Period | ICUCW | S&P 500 | Difference | ICUCW per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -33.1% | -0.9% | −32.2 pts | ||
| 3 months | -43.5% | +2.1% | −45.7 pts | ||
| Year to date | -3.5% | +11.7% | −15.2 pts | ||
| 1 year | -71.3% | +12.4% | −83.7 pts | ||
| 3 years | -78.1% | +88.6% | −166.7 pts | -39.7% | +23.5% |
| 5 years | -97.9% | +75.9% | −173.8 pts | -53.8% | +12.0% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Press releases
Releases SeaStar Medical filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Results
- Results
- News
- Results
About SeaStar Medical
Surgical & Medical Instruments & Apparatus
SeaStar Medical Holding Corporation is a commercial-stage healthcare company focused on developing therapies for critically ill patients facing organ failure and severe inflammation. The company develops the Selective Cytopheretic Device, an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy circuits to selectively deactivate hyperinflammatory white blood cells. Its initial commercial offering, Quelimmune, provides cell-directed therapy for pediatric patients suffering from acute kidney injury associated with sepsis. The company primarily serves hospital intensive care units and pediatric medical centers treating patients with life-threatening hyperinflammatory conditions.
Company profile, executives and historySeaStar Medical stock: common questions
What is SeaStar Medical's stock price?
ICUCW closed at $0.01 on Oct 30, 2026, down 34.73% on the day. Over the past 52 weeks it traded between $2.07 and $6.00.
What is SeaStar Medical's market cap?
SeaStar Medical was worth $9.87M at the close on Oct 30, 2026: the share price times the diluted shares outstanding.
What is ICUCW's P/E ratio?
SeaStar Medical lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.93), so it has no meaningful P/E ratio.
How much revenue does SeaStar Medical make?
SeaStar Medical reported revenue of $1.71M for the twelve months to Jun 30, 2026, up 123.6% from a year earlier.
Does SeaStar Medical pay a dividend?
No. SeaStar Medical has not paid a cash dividend over the last twelve months.
When does SeaStar Medical report earnings next?
SeaStar Medical is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ICUCW stock performed over the past year?
Including dividends, ICUCW returned -71.3% over the past year, against +12.4% for the S&P 500.
Who are SeaStar Medical's competitors?
Companies most similar to SeaStar Medical by business, industry and size include RNXT, OSRH, HRGN, PLSE, AURX.